Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
Article in Journal of gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Tingyan ShiOvarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-5356-0365
Libing XiangOvarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-8009-6521
Jianqing ZhuDepartment of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0001-5736-7397
Jihong LiuDepartment of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0001-9711-2428
Ping ZhangDepartment of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0003-1995-9775
Huaying WangDepartment of Gynecologic Oncology, Fudan University Cancer Hospital, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID 0000-0002-3780-4497
Yanling FengDepartment of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0002-3485-1490
Tao ZhuDepartment of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0002-2921-4067
Yingli ZhangDepartment of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0001-6929-8480
Aijun YuDepartment of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0003-0142-7658
Wei JiangDepartment of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.ORCID 0000-0003-0596-7811
Xipeng WangDepartment of Obstetrics and Gynecology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-7555-4185
Yaping ZhuDepartment of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China.ORCID 0000-0003-3163-3815
Sufang WuDepartment of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China.ORCID 0000-0003-1216-4814
Yincheng TengDepartment of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-6451-4479
Jiejie ZhangDepartment of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.ORCID 0000-0001-8114-1988
Rong JiangOvarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-2138-167X
Huixun JiaClinical Statistics Center, Shanghai General Hospital, Shanghai, China.ORCID 0000-0001-9341-5587
Rongyu ZangOvarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-1334-2398
Zhejiang Cancer Hospital · CNFudan University · CNShanghai First People's Hospital · CNSun Yat-sen University · CNFudan University Shanghai Cancer Center · CNObstetrics and Gynecology Hospital of Fudan University · CNShanghai Clinical Research Center · CNShanghai Sixth People's Hospital · CNXinHua Hospital · CN
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. · full record | OpenQuestion